Company intelligence / Profile preview

eismann

München/Munich, Germanyeismann.com ↗

Ownership: Private
Development stage: Commercial

Overview

Eisbach Bio is a clinical-stage biotech company developing first-in-class small molecules targeting helicase enzymes essential for tumor survival, particularly in cancers with resistance to PARP inhibitors. Their lead compound EIS-12656 has shown promising safety and activity in preclinical studies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Cancer Focus Fund (investment partnership)Collaboration with MD Anderson for advancing clinical trials

Beyond the preview

Go deeper on eismann.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eismann.

Explore the full profile